Key result
Evidence for antithrombotic therapy in diabetes lacks dedicated trials, relying mostly on broader study subgroups.
Why the study?
Evidence on antithrombotic therapy in primary and secondary prevention is limited due to a scarcity of dedicated randomized trials in patients with diabetes mellitus.
This review highlights the current state of knowledge and the scarcity of dedicated randomized trials regarding antithrombotic therapy in diabetic patients with coronary artery disease.
Limited dedicated trials advise cautious antithrombotic decisions in diabetic CAD; leaves open the need for targeted RCTs.
Diabetes mellitus is a complex disease that leads to long-term damage to various organ systems. Among the numerous cardiovascular disease-related complications, thrombotic events frequently occur in patients with diabetes. Although guidelines exist for treating and preventing most diabetes-related co-morbidities, the evidence on antithrombotic therapy in primary and secondary prevention is limited due to the scarcity of randomized trials dedicated to patients with diabetes mellitus. Most of the available data are derived from studies that only included a small proportion of patients with diabetes. The present review provides an overview of the status of knowledge on antiplatelet and anticoagulation therapy in patients with diabetes, focusing on the risk-benefit balance of these therapies and future treatment strategies.
No takes yet. Share an insight, caveat, or question.
Nicolas et al. (2021) conducted a review in Diabetes mellitus with coronary artery disease. Antiplatelet and anticoagulation therapy was evaluated. Current evidence on antithrombotic therapy in diabetic patients is limited by a scarcity of dedicated randomized trials, with most data derived from subgroups of broader studies.